UBS Group’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-2,925
| Closed | -$7K | – | 8811 |
|
|
2020
Q2 | $7K | Hold |
2,925
| – | – | ﹤0.01% | 7263 |
|
|
2020
Q1 | $4K | Buy |
2,925
+25
| +0.9% | +$51 | ﹤0.01% | 7451 |
|
|
2019
Q4 | $8K | Buy |
2,900
+336
| +13% | +$1.08K | ﹤0.01% | 7422 |
|
|
2019
Q3 | $14K | Sell |
2,564
-15,675
| -86% | -$104K | ﹤0.01% | 6979 |
|
|
2019
Q2 | $175K | Sell |
18,239
-676
| -4% | -$12.4K | ﹤0.01% | 4998 |
|
|
2019
Q1 | $507K | Sell |
18,915
-792
| -4% | -$20.2K | ﹤0.01% | 4057 |
|
|
2018
Q4 | $445K | Buy |
19,707
+5,489
| +39% | +$215K | ﹤0.01% | 4360 |
|
|
2018
Q3 | $785K | Buy |
14,218
+4,574
| +47% | +$292K | ﹤0.01% | 4059 |
|
|
2018
Q2 | $689K | Sell |
9,644
-8,751
| -48% | -$618K | ﹤0.01% | 4075 |
|
|
2018
Q1 | $1.13M | Buy |
+18,395
| New | +$1.61M | ﹤0.01% | 3611 |
|
|
2017
Q3 | – | Sell |
-33
| Closed | -$5K | – | 8140 |
|
|
2017
Q2 | $5K | Sell |
33
-830
| -96% | -$128K | ﹤0.01% | 7153 |
|
|
2017
Q1 | $159K | Buy |
863
+19
| +2% | +$2.13K | ﹤0.01% | 4788 |
|
|
2016
Q4 | $68K | Buy |
844
+534
| +172% | +$42.2K | ﹤0.01% | 5592 |
|
|
2016
Q3 | $24K | Buy |
310
+290
| +1,450% | +$23.2K | ﹤0.01% | 6168 |
|
|
2016
Q2 | $2K | Sell |
20
-505
| -96% | -$46.3K | ﹤0.01% | 7472 |
|
|
2016
Q1 | $48K | Sell |
525
-1,047
| -67% | -$105K | ﹤0.01% | 5545 |
|
|
2015
Q4 | $316K | Sell |
1,572
-449
| -22% | -$89.6K | ﹤0.01% | 4311 |
|
|
2015
Q3 | $302K | Buy |
2,021
+93
| +5% | +$68.3K | ﹤0.01% | 4297 |
|
|
2015
Q2 | $1.83M | Sell |
1,928
-85
| -4% | -$69.5K | ﹤0.01% | 3059 |
|
|
2015
Q1 | $1.48M | Buy |
2,013
+1,561
| +345% | +$1.17M | ﹤0.01% | 3213 |
|
|
2014
Q4 | $359K | Buy |
+452
| New | +$243K | ﹤0.01% | 4500 |
|
UBS Group's TTPH Position: Q3 2020 in Review
UBS Group sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 2,925 shares — an estimated $7K sold.
UBS Group first reported a position in TTPH in Q4 2014 and held it in 21 quarters. The position peaked at $1.83M in Q2 2015. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.
- UBS Group reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- UBS Group sold 2,925 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020, an estimated $7K.
- UBS Group first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2014 and held it in 21 quarters.
- UBS Group's Tetraphase Pharmaceuticals, Inc. position peaked at $1.83M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.
Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.